List of Therapeutic Companies in South Korea - 120

At 1STBIO, we strive to transform the lives of patients by relentlessly discovering and developing novel therapeutics to address areas of significant unmet need. Inspired by science and innovation, we dedicate our expertise and experience in drug development to bring forward a pioneering change.

AbClon was founded in 2010 by a consortium of Korean and Swedish experts in antibody development. Our mission is to cure once incurable diseases such as cancer.

ABL Bio Inc. (Kosdaq: 298380) is a South Korean biotechnology company dedicated to the development of bispecific antibody therapeutics to improve and save people's lives. With our BsAb platforms ‘Grabody-T,’ ‘Grabody-I’ and ‘Grabody-B,’ we have built a robust pipeline of multiple clinical and pre-clinical stage drug candidates. In the oncology area, we have developed Grabody-T, a modular 4-1BB engaging platform that has demonstrated excellent efficacy and safety. We also created a next-generation antibody drug conjugate program to treat various cancers. In the neurodegenerative disorder space, we have developed Grabody-B platform, which is designed to maximize blood-brain barrier (BBB) penetration. Grabody-B is applicable to various CNS targets across a plethora of neurological disorders, potentially providing a breakthrough to address the high unmet medical needs in neurodegeneration. We continue to actively expand and advance our pipeline through global strategic partnerships. For more information, please visit http://ablbio.com

We aim to advance current state-of-the-art AI drug discovery technologies and transform high-cost, low-efficiency drug discovery practices into rapid, efficient discovery, ultimately leading to high success rates in the clinical phase. Our award-winning AI drug discovery platform enables the direct discovery of high potency drugs that induce desired cellular-level activity with minimal off-target effects and toxicity. AIGEN Sciences will revolutionize AI-based drug discovery.

ALTEOGEN Inc., Daejeon(fifth-largest metropolis)-based in South Korea, is a leading biopharmaceutical company with a leading edge pipeline of novel biologics such as next generation biobetters including long-acting therapeutic proteins, Antibody-Drug Conjugate (ADC) therapeutic antibodies and monoclonal antibody biosimilars. The company was founded in 2008 and listed in KOSDAQ stock market (KRX:196170). Our innovative NexP™ fusion technology is applied to various proteins and peptides to allow longer activities in human beings. Long-acting human Growth Hormone, long-acting exenatide (for diabetes) and long-acting Factor VIIa (for hemophilia) are developed with the NexP™ fusion technology. Our proprietary ADC technology, NexMab™ ADC technology is well suited for the targeted therapy for the cancer drugs with lower side effect and better efficacy. With this NexMab™ ADC technology, we are developing ADC therapeutics for breast/gastric cancer and ovarian cancer. Alteogen's mostly distinguished Hybrozyme™ technology to a human hyaluronidase, which has been widely used to improve the absorption of drug biologics delivered via subcutaneous injection. The novel human hyaluronidase based on Hybrozyme™ technology showed improved enzymatic activity and thermal stability. Based on long and rich experiences, Alteogen has quickly developed its own cell lines with high expression, efficient process (upstream and downstream), and optimized analysis methods for monoclonal antibody biosimilars including Herceptin preparing for the phase 3 trials upon completion of global phase 2 testing, SC formulation of Herceptin biosimilar as well as working on Eylea biosimilar.

APITBIO is a biotech company that specializes in antibody therapeutics research and development.

Biopharmaceutical company focused on developing and manufacturing biosimilar products, new protein drugs and bispecific antibodies

Aptamer Sciences Inc. is a privately held biotech company focused on commercializing cutting-edge technologies for analysis of proteins, based on its proprietary aptamer technology platforms. Aptamer Sciences is dedicated to develop the aptamer technologies to generate high quality aptamer and in broad applications of research, diagnosis and therapeutics. Compared to conventional aptamer generating technologies, Aptamer Sciences has developed advanced aptamer technologies and thus can generate aptamers more efficiently with superior binding affinity. Aptamer Sciences has ongoing collaboration relationships with several industry partners. The Company also has research collaboration with several universities, hospitals and research organizations. Aptamer Sciences was founded in 2011 by researchers from POSTECH BIOTECH CENTER and is based in Pohang, South Korea. Aptamer Sciences is currently funded by aptamer service revenue and grants, as well as by investments from strategic investors.

AriBio is a clinical-stage biotech company located in Seongnam, South Korea focused on developing novel therapeutics for neurodegenerative diseases. The US office is located in San Diego managing global clinical operations and regulatory affairs. The lead asset, AR1001, is entering a global phase 3 program this year.

Art Blood Co., Ltd. is a company that is building/developing a cell-based in vitro blood production system to solve the problem of blood for transfusion that is in short supply worldwide and has side effects. In addition, we are developing a platform to provide reagent red blood cells used to detect transfusion-related antibodies and therapeutic red blood cells that transport and express various therapeutic agents and immunostimulants.

Aston Sci., a clinical stage biopharmaceutical company that is currently focusing on clinical development of innovative medicines in oncology, immunology, and geriatrics, including therapeutic cancer vaccines. Aston Sci. is constantly listening to the changing needs of the patients and will continue to move forward to improve the lives of patients who suffer from cancer recurrence, metastasis, or side effects during cancer treatment.

Autophagy Science is a drug development company specializing in the development of treatments for intractable diseases.

Avelos Therapeutics is a precision medicine company in the clinical stage that finds, creates, and sells targeted therapeutics. They are the developer of biomarker-driven anti-cancer targeted therapies and have raised a total funding of $8M over 1 round from 7 investors.

bBHC Stem Cell Treatment & Research Institute discovered the newly Elicited pluripotent Stem Cell without side effects which is called nEPS. We've been differentiated nEPS into endoderm,mesoderm and ectoderm. Our goal is overcome to incurable diseas using in nEPS.

BIOINFRA is focused on helping win the war on cancer through cost-effective cancer screening. BIOINFRA Inc., established in 2001 at Seoul National University Cancer Research Institute has dedicated more than 15 years of research to develop an innovative in vitro cancer screening technology. In particular, under the leadership of Professor Chul-Woo Kim of Seoul National University College of Medicine, BIOINFRA developed the “Smart Cancer Screening Test”, a cancer screening test that effectively screens for cancer with only a few drops of blood. According to our proprietary research consisting of more than 20,000 cancer and non-cancer blood samples, Smart Cancer Screening Test correctly identified a meaningfully higher number of cancer and non-cancer blood samples when compare to blood-based, single tumor marker test. We are dedicated to delivering the most accurate results, providing physicians and the medical community with world-class service, and providing individuals with a convenient, cost-effective cancer screening solution.

Bionoxx is a research and development company that develops immune regulation-based anticancer drugs to conquer cancer diseases.

Bio-Pharm Solutions is a new drug developer specializing in the central nervous system and rare diseases.

BIORCHESTRA is an innovative biotech company focusing on research and development of ribonucleic acid (RNA) based therapeutics. Our goal is to change the therapeutic paradigm from treating the symptoms to providing fundamental cure of the diseases. As we are making steady progress in the clinical development, we seek global partners to collaborate in the areas of research and development (R&D) and the commercialization.

BMI KOREA: A DYNAMICALLY-GROWING BIOPHARMACEUTICAL COMPANY, ALWAYS CHALLENGING FOR HEALTHY LIFE OF HUMAN-BEING. BMI is a pharmaceutical and biotechnology company based in South Korea that focuses on development and commercialization of new medicines (incl. biologics) and medical devices. BMI started to operate in 2005, and for more than a decade it has been growing with successful development of new medicines and biologics based on its own novel technologies and know-hows. BMI has specialized in sterile formulation and has developed many products such as HA, PN, PDRN and Botulinum Toxin etc. One of main BMI’s assets is “Hyaluronidase”. BMI has led the market over the last 10 years with two formulations: (A liquid sterile-brand: “Hirax® and a lyophilized sterile power vial- brand: “BM Hylunidase ®”). With these experiences and expertise, BMI has recently developed new generation of it, “Recombinant Hyaluronidase” which is well-known to be used for changing monoclonal antibody’s formulation from IV to SC. On top of that, BMI provides integrated CDMO services to help other pharmaceuticals and biotech companies develop and commercialize medicines. With the most advanced cGMP facilities and R&D center in JEJU and OSONG, BMI can deliver the highly qualified DS, DP and ensure partners’ success to IND, NDA and BLA. Full of speed and customer tailored flexibility are the main strengths.

BMI KOREA: A DYNAMICALLY-GROWING BIOPHARMACEUTICAL COMPANY, ALWAYS CHALLENGING FOR HEALTHY LIFE OF HUMAN-BEING. BMI is a pharmaceutical and biotechnology company based in South Korea that focuses on development and commercialization of new medicines (incl. biologics) and medical devices. BMI started to operate in 2005, and for more than a decade it has been growing with successful development of new medicines and biologics based on its own novel technologies and know-hows. BMI has specialized in sterile formulation and has developed many products such as HA, PN, PDRN and Botulinum Toxin etc. One of main BMI’s assets is “Hyaluronidase”. BMI has led the market over the last 10 years with two formulations: (A liquid sterile-brand: “Hirax® and a lyophilized sterile power vial- brand: “BM Hylunidase ®”). With these experiences and expertise, BMI has recently developed new generation of it, “Recombinant Hyaluronidase” which is well-known to be used for changing monoclonal antibody’s formulation from IV to SC. On top of that, BMI provides integrated CDMO services to help other pharmaceuticals and biotech companies develop and commercialize medicines. With the most advanced cGMP facilities and R&D center in JEJU and OSONG, BMI can deliver the highly qualified DS, DP and ensure partners’ success to IND, NDA and BLA. Full of speed and customer tailored flexibility are the main strengths. For more information, please visit our website below: www.bmikr.co.kr

Boryung is a healthcare investment company founded in 1957 and headquartered in Seoul, South Korea. Following the company’s mission to become an indispensable contributor to human health, we have expanded our business portfolio to the space healthcare industry. Recognizing space as a new growth realm, we acknowledge the increasing number of individuals anticipated to embark on extended space missions, highlighting the importance of ensuring human survival in the hostile space environment. Hence, Boryung believes there will be substantial opportunities to foster new technologies and meet the emerging needs in this field.

Founded in 2019, Brexogen is at the forefront of biotechnological innovation, dedicated to transforming the treatment of incurable diseases through our proprietary BG-Platform technology. As a pioneering bioventure, we specialize in the development of cell-free therapies, leveraging the untapped potential of stem cell derived exosomes. Our mission intertwines groundbreaking research with practical healthcare solutions. As we gear up for global expansion, our strategy emphasizes understanding local markets, forging strategic partnerships, continuous innovation, and engaging with the medical community to promote the benefits of exosome therapy. Rooted in South Korea, Brexogen is on a trajectory to enhance healthcare outcomes worldwide. We're dedicated to leading the charge in biotechnological innovation, offering accessible, effective treatments on a global scale. Join our journey as we strive for a healthier future across communities globally.

Bridge Biotherapeutics Inc., based in the Republic of Korea, US, and China, is a publicly-traded clinical-stage biotech company founded in 2015. Bridge Biotherapeutics is engaged in the discovery and development of novel therapeutics, focusing on therapeutic areas with high unmet needs such as ulcerative colitis, fibrotic diseases, and cancers. The company is developing BBT-401, a first-in-class Pellino-1 inhibitor for the treatment of ulcerative colitis, BBT-877, a novel autotaxin inhibitor for the treatment of fibrotic diseases including idiopathic pulmonary fibrosis (IPF), and BBT-176, a potent targeted cancer therapy for non-small cell lung cancer (NSCLC) with C797S triple EGFR mutations.

CanariaBio is a biopharmaceutical company that focuses on developing and commercializing immunotherapies for cancer, utilizing a technology platform of tumor antigen specific monoclonal immunoglobulins targeting CA-125, MUC1, PSA and Her2/neu.

Cellatose Therapeutics Co., Ltd. is a company specializing in cell therapy development that was established in August 2017 with the goal of ‘ resolving unmet needs for incurable diseases . ’ The nation's best cell therapy research and development experts are gathering to discover differentiated cell and platform technologies and promote the commercialization of cell therapy products.

Our company is an anti-cancer immunotherapy and infectious disease prevention vaccine development company that started from the laboratory of the College of Pharmacy at Seoul National University on December 11, 2006. We have developed a total of 5 types of BVAC pipeline, a personalized anti-cancer immunotherapy vaccine based on our own original technology, CeliVax, and COVID-19 vaccines. A vaccine to prevent -19 is being developed.

Celltrion is a leading biopharmaceutical company that specializes in research, development and manufacturing of innovative therapeutics. We are committed to delivering innovative and affordable medications to promote patients’ access to advanced therapies. We have been at the forefront of biotherapeutic development uncovering new ways of targeting the drivers of disease by creating next-generation biologics and small molecule products. For additional information on our guidelines, please visit: http://tinyurl.com/bdh9bxs9

CHA Bio Group is continuing its challenge to become the best in various initial achievements in the bio and healthcare fields. We are developing and producing advanced biopharmaceuticals, including cell and gene therapy products and vaccines, based on our global R&D capabilities, such as our unique ‘CHA Bio ecosystem': Academic, Research, Medical Network, and Bio-Industry Business, the world's largest cell library, and our independently developed vaccine adjuvant platform. We will leap forward as a true global bio company centered on the third-generation CGT CDMO and global healthcare business.

CHA Biotech is the only company in Korea that has a collective eco-system integrating CHA Medical University, CHA Advanced Research Institute, and CHA Hospitals within the group collaborating to develop new drugs by conducting basic research and clinical trials up to commercialization. CHA Biotech has the world's largest cell library (embryonic and adult stem cells, immune cells) that can be applied to cure various diseases, and has differentiated technology including 88 globally registered patents for cell technology. Based on our R&D competency, the company develops cell and gene therapies for diseases that are unmet and are in high demand for cure such as cancer, incurable diseases, and aging-related diseases.

CJ Bioscience Global No.1 Microbiome Company CJ Bioscience is pioneering development of next-generation biopharmaceuticals for microbiome health with its leading edge in the field of ‘Wellness'. We aim to provide healthcare solutions for unmet medical needs by examining the relationships between human microbiomes and various diseases. In addition, CJ Bioscience, which uses leading world-class bioinformatic analysis technology, will discover promising candidates that can be used in the treatment of incurable diseases, and accelerate the development of new drugs utilizing our ‘Ez-Mx™ Platform' to become the global No. 1 microbiome company. Microbiome We plan to enter clinical trials (Phase 1) of a new drug development pipeline for treatment of immuno-oncology, autoimmune, and CNS (Central Nervous System) diseases and to promote technology export through joint research with Big Pharma. Also, we are constructing a ‘Ez-Mx™ Platform' by expanding on cohort studies (comparative disease research) and securing global microbiome big data. The next generation of genomic analysis We plan to expand our business area from next generation sequencing (NGS)-based microbiome genomic analysis to microbial infection diagnosis. We will further upgrade our state-of-the-art NGS and bioinformatics (BI) total solution services. We are expanding the global business capabilities of EzBioCloud, a global standard bioinformatic analysis service made for researchers combining a curated microbiome database and artificial intelligence (AI) technology, and TrueBacID, the world's first genome-based infection diagnosis service. In addition, through the global launch of Gut Inside, an intestinal.

Clinomics provides early diagnosis of cancer/diseases based on genome and pursues to overcome aging and diseases through liquid biopsy and Multi-Omics technology.COVID-19: EUA (02/2021)

(주)씨앤큐어

About Coreline soft We develop AI-based imaging diagnosis package, specializing in lungs. This includes lung cancer screening(LCS), COPD quantification, and coronary artery calcification (CAC) systems, we call it B3 systems, covering the 3 big diseases in thoracic imaging. More in-depth lung diagnosis products with analysis such as texture analysis for ILD/IPF and pneumonia detection including COVID-19 are soon to be expected.   √ The Official solution provider for the nationwide lung cancer screening program in Korea (K- LUCAS) from 2017, which is the 2nd state-level-reimbursed LCS program following the US from 2015 √ The Official solution provider of 4-ITLR project by the Nelson Team (Erasmus MC and iDNA in the Netherlands), which is a large early detection LCS Trial-based on B3 system. Two hospitals in Germany, DKFZ Heidelberg and Univ Hosp of Essen, are the members of this trial and our systems will be implemented in these hospitals from 2021. √ Imminent Official solution provider for the German Trial by multi-university hospitals which is a pilot project to prove a national support necessary for LCS in Germany. √ Our COPD systems are used by European customers such as NZ Leuven Belgium, Leicester Univ UK, Parma Univ Italy obtaining the appraisal as the best of breed for early detection, phenotyping, surgery support, and etc.

CorestemChemon is a global biotechnology corporation centered on stem cell-based new drug development and non-clinical research divisions. Motivated by the urgent need for medication for patients, the bio-pharmaceuticals division remains dedicated to research and development. In 2014, the unit successfully commercialized Neuronata-R inj, a stem cell therapy for the rare disease Amyotrophic Lateral Sclerosis (ALS), making it the fifth stem cell therapy approved for use globally. Alongside ALS treatment, the division has pipelines for various diseases such as lupus, Neuromyelitis Optica (NMO), and multiple system atrophy (MSA). Leveraging the success of the ALS stem cell therapy, the unit plans to concentrate on developing treatments for rare and incurable neurological and autoimmune diseases to dominate new market.

Curamys is a biotechnology company that develops cell fusion technology to cure intractable diseases.

Curocell is a cell therapy company that discovers and develops CAR-T therapies for cancer. The company's current efforts focus on unleashing the body’s immune system through broad-spectrum CAR-T technologies to treat blood cancers, as well as solid cancers. The company's programmed T cell product candidates are differentiated by incorporation of T cell modifying technology designed to effectively overcoming the immune suppression, and thereby offers greater efficacy compared to the current CAR-T cell technology.

Dong-A ST is a company established in March 2013 following the restructuring of the former Dong-A Pharmaceutical into a holding company. Our company focuses on the development and sale of specialized pharmaceuticals (ETC) and is dedicated to the philosophy of "Our company's social contribution is in new drug development." With state-of-the-art research facilities such as the Yongin Research Center established in 1977 and the completion of the Songdo Research Center in 2021, Dong-A ST has been striving for innovative global new drug development with excellent research and development capabilities. For many years, by consistently investing more than 10% of its revenue in R&D, we have successfully developed multiple proprietary novel drugs, including Stillen, Zydena, Motilitone, Sivextro, and Suganon/Sugamet.

Developing new radiopharmaceuticals for cancer diagnosis & treatment, and achieving successful commercialization locally & globally

Elixapharmatech is a bio-drug development company that develops immuno-inflammation suppression drugs.

Enzychem Lifesciences, Corp. (KOSDAQ:183490) is a global biopharmaceutical company headquartered in Seoul, Korea, which is dedicated to developing new drugs and APIs (Active Pharmaceutical Ingredients). Since its foundation in 1999, Enzychem Lifesciences has been striving to develop new and innovative treatments capable of addressing unmet medical needs with R&D-driven approaches under its grand mission of "Saving Human Lives by Overcoming Unmet Medical Needs"​ EC-18, the lead compound of Enzychem Lifesciences, is an immune modulator driven from deer antler that has the potential to be used for a variety of indications. At present, three clinical trials for different indications are being conducted; Chemotherapy Induced Neutropenia (CIN), Chemoradiation Induced Oral Mucositis (CRIOM), and Acute Radiation Syndrome (ARS). In order to facilitate the clinical trial process, Enzychem launched a US operation office in New Jersey on June 28, 2018. Currently, Enzychem Lifesciences is one of the fastest growing life science companies in KOSDAQ Stock Exchange in terms of market capitalization. The company is headquartered in Seoul, Korea.

Eutilex is a KOSDAQ listed company that researches and develops new drugs with a focus on immunotherapy

GC Biopharma (formerly known as Green Cross Corporation, KRX: 006280) is a biopharmaceutical company that delivers life-saving and life-sustaining protein therapeutics and vaccines. Headquartered in Yongin, South Korea, GC Biopharma is one of the leading plasma protein product manufacturers in the world and has been dedicated to quality healthcare solutions for more than half a century.

Since 2008, GemVax & KAEL has operated as a cutting-edge research and development company developing proprietary peptide drug, GV1001, for treatment against various cancers and neurodegenerative disease including Alzheimer's disease and Progressive Supranuclear palsy. The fundamental driving purpose of our innovative pharmaceutical research is to facilitate significant improvements to human life through the introduction of advanced medical technology and innovation rooted in advanced scientific measures. At GemVax, we take pride in our proactive approach to medical research, and our progressive peptide-drug focused advancements have played a crucial role in the incessant global battle against incurable disease.

GeneCraft is a pre-clinical-stage biotech company dedicated to improving treatment and clinical outcomes for patients through gene therapy that harness the power of the immune system. The company's technology allows for the development of gene therapies for the treatment of cancer.

Genexine has robust R&D pipelines in clinical and pre-clinical stages based on long-acting Fc-fusion technology and therapeutic DNA vaccine technology. In the clinical stage, Genexine has GX-H9 (long-acting human growth hormone, hGH-hyFc) co-developed with Handok for both adult and pediatric GHD, currently finished multinational Phase 2 trials and preparing for global Phase 3 trials. GX-188E therapeutic DNA vaccine for HPV-associated diseases is in Phase 2 in Europe and Korea for Cervical Intraepithelial Neoplasia II/III. Combined with Merck’s Keytruda, GX-188E recently is in Phase 1b/2a trial for cervical cancer. HyLeukin-7 (Immuno-oncology agent, IL-7-hyFc) has finished Phase 1 trial in Korea and received IND approval from US FDA. Currently, Genexine is running more than 7 clinical trials globally. In addition to collaboration with Merck, Genexine has strategic partnerships with leading Asian companies such as Shanghai Fosun Pharma, Tasly Pharma, Simcere Pharma, Kalbe Pharma, and Korean big Pharma companies such as Handok, Green Cross and Yuhan.

Genkore is a Korea-based biotech company specializing in genetic scissors and gene therapy. They have developed a healthcare platform designed to provide gene therapy for medical emergencies that may occur in the future. The company has also announced collaborations with US-based companies for in vivo gene editing therapy and has signed deals worth up to $650M for gene editing tech. Genkore is also involved in plant biotechnology and has a strong focus on research and development.

Genome & Company is a global pharmaceutical bio company that focuses on research and development of microbiome medicines and new drug targets ('targets')-based immunotherapy agents based on abundant clinical data and multi-omics technology (Multi-Omics). Since its establishment in 2015, Genome & Company has been a global leader in the field of microbiome immuno-oncology drugs and new target immuno-oncology drugs, implementing the 'Bed-to-Bench' strategy (clinical data-based research) of GNOCLE™, an independent drug candidate discovery platform. Development Strategy), we have collaborated with major domestic and foreign pharmaceutical and bio companies and research-oriented hospitals. In the future, Genome & Company will not only accelerate the development of innovative treatments for high unmet medical needs by utilizing the microbiome and new drug targets, but will also strengthen its production and commercialization capabilities to become a fully integrated pharmaceutical bio company.

Founded in 2016 in South Korea, Genuv(지뉴브) is a clinical-stage biopharma that specializes in discovering and developing innovative therapeutics based on own platform technologies for drug discovery. GENUV is dedicated to the discovery and development of life-transforming therapeutics for patients with debilitating diseases. To do this, we passionately endeavor to advance our own platform technologies and capitalize on our strengths in multi-disciplinary collaborations with external partners. Our current research and development focus is on a) small molecule drugs to treat neurodegenerative diseases through neurogenesis and neural homeostasis and b) antibody drugs for immuno-oncology treatment.

HanAll Biopharma is a global biopharmaceutical company committed to discovering and developing innovative treatments for various diseases. The company has entered into joint research and development agreements with other pharmaceutical companies to explore potential treatments. HanAll Biopharma is dedicated to advancing healthcare through strategic partnerships and cutting-edge research.

HANDOK is a leading innovation-driven pharmaceutical/health-care company in Korea, develops, manufactures and distributes healthcare solutions to improve the health and quality of human life. It was founded in 1954 and has been dedicated to developing and providing innovative pharmaceutical products (Prescription drugs & OTC drugs), medical devices, and in vitro diagnostics. Handok grew with its joint venture partner Hoechst/Aventis/Sanofi from 1964 to 2012. In several areas Handok has also established strategic collaborations with multiple multinational pharmaceutical companies. Handok ended its joint venture relationship with Sanofi in 2012. In 2013, Handok changed its company name from Handok Pharmaceutical Co., Ltd to Handok Inc. and declared its vision to become, “The Health Innovator” as Korea’s leading global healthcare company. “모두의 더 건강한 삶을 위해 대한민국을 대표하는 The Health Innovator가 되겠습니다” 한독은 1954년 창업 이래 세계 유수 제약사들과 협력관계를 맺으며 변화와 성장을 거듭해 왔습니다. 1964년 독일 훽스트와의 합작을 시작으로 합작 파트너가 아벤티스, 사노피로 바뀌는 48년간, 선진 제약기술과 우수의약품을 한국에 도입하며 대한민국 제약산업의 선진화를 이끌었습니다. 1992년 본사 사옥을 강남 테헤란로로 이전하고 충북 음성에 1995년 국내 최고의 GMP 생산시설을 준공한 한독은 일찍이 선진 경영기법과 마케팅 전략을 도입하고 글로벌스탠다드 시스템(Global Standard System)을 갖춰왔습니다. 2012년 10월 독자기업이 되었으며, 2013년 한독약품에서 한독으로 사명을 변경했습니다. 한독은 대한민국을 대표하는 글로벌 토탈헬스케어 기업으로서 The Health Innovator가 되겠다는 비전을 선포하고 바이오 벤처 ‘제넥신’ 지분투자, 세계 1위 제네릭 기업인 이스라엘 테바와 합작회사 ‘한독테바’ 설립, 케토톱으로 유명한 ‘태평양제약 제약사업부문’ 인수, 치료 의료기기 벤처 ‘칼로스메디칼’ 설립, 일본 기능성 원료 회사 ‘테라밸류즈’ 인수 등 미래 성장 동력을 확보하고 글로벌 진출을 확대하기 위한 혁신적인 도전을 이어오고 있습니다. 현재 한독은 전문의약품, 일반의약품, 진단시약과 의료기기, 건강기능식품, 특수의료용도 식품 등 다양한 헬스케어 제품과 서비스를 제공하고 있습니다. 또, 한독은 모두의 더 건강한 삶을 위해 오픈 이노베이션 전략으로 경쟁력을 갖춘 연구개발을 펼쳐 나가고 있으며 혁신 바이오의약품, 표적항암제, 의료기기 개발에 집중하고 있습니다. 2022년 한독은 서울시 강서구 마곡지구에 ‘한독 퓨쳐 콤플렉스’를 준공해 분리되어 있었던 제품개발연구소와 신약개발연구소를 한독 퓨쳐콤플렉스로 통합 이전하며 R&D 역량을 강화했습니다. 더불어 초기 단계의 바이오스타트업을 발굴하고 육성하는 "이노큐브"를 통해 신약개발을 위한 이노베이션플랫폼을 확장했습니다. 한독은 남들보다 한발 앞서, 높은 기준의 윤리경영과 투명경영을 실천하고 있으며, 직원이 행복해야 기업이 함께 성장한다는 믿음으로 직원 스스로 즐겁게 일할 수 있는 기업문화를 만들어 오고 있습니다.

Biologics, Small Molecules

Hanmi Pharmaceutical, Co., Ltd., headquartered in Seoul, South Korea, and established in 1973, has become one of the largest companies not only in Korea but also within the region, selling over 200 products worldwide. Today, Hanmi is also recognized as the No.1 R&D investing company in Korea, spending over 10~15% of the company’s annual revenue in developing next generation Platform Technologies & NCE products.

Helixmith is a gene therapy company headquartered in Seoul, Korea, developing new and innovative biopharmaceuticals for previously untreated diseases, and is listed on KOSDAQ. The company has an extensive gene therapy pipeline, including a CAR-T program targeting several different types of solid tumors and an AAV vector program targeting neuromuscular diseases. Engensis (VM202), a more advanced pipeline candidate, is a plasmid DNA therapy being studied for DPN, diabetic foot ulcers, claudication, amyotrophic lateral sclerosis (Phase 2 beginning in late 2020), coronary artery disease and Charcot-Marie-Tooth disease. Helixmith clinical development activities are based in San Diego, California,

Hyundai Pharm is eager to share our happiness to all of you. Our all executives and staffs have been building up happiness in Hyundai Pharm as if we are a family. Through this inside circumstance, we are performing moral and qualified management to make all costumers be satisfied with us. Moreover, we have tried to carry out social responsibility with conducting social-minded activities consistently to make the sociality be more peaceful and attractive. We are now going to the next step for the global company. Fear for the changes could be hard to expect for better tomorrow. Hyundai Pharm has been growing up for the best pharmaceutical company in the world through our vision that is “going to the next step with changes and innovation.” For that reason, we are focusing on R&D more to make a new product which contributes to the everyone’s happiness, and eager to be a leading company with our speedy sharing of information and decision. We firmly promise that we will be the best pharmaceutical company in the world in spite of the rapidly changing management circumstances and do our best to achieve our goal.

ILDONG - A global healthcare company dedicated to customer-centric values As a leading pharmaceutical company in South Korea, we have been dedicated and committed to the development and supply of superior pharmaceutical products that contribute to the health and well-being of people around the world. We are steadfast in our vision of continuously growing with our customers as a leading global company by providing solutions for disease prevention and developing new solutions for healthier and happier lives. Ildong has earned the trust of our customers with our ethical drugs franchise for chronic disease and cancer therapies, antibiotics, and digestive and circulatory drugs, in addition to our well-known OTC brands such as Biovita(probiotics product) and Aronamin(multivitamin). We are on the road to reaching our vision of becoming a global total healthcare company with various new drug pipelines including Besivo(hepatitis B therapy), which is the 28th novel drug in South Korea, as well as new innovative drug pipelines and new businesses for health functional foods, medical devices, cosmetics, and beverages.

At ILIAS Biologics, we dedicate ourselves to the paradigm-shifting advances in human medicine. We are specialized in developing engineered exosomes by loading large therapeutic payloads inside exosomes via our proprietary platform technology, EXPLOR®. By harnessing the power of our engineered exosomes, we can deliver therapeutic proteins to the undruggable intracellular pathways to treat life-threatening and hard-to-treat rare diseases. With a strong belief and the power of open innovation, we are expanding our global network of research and business alliances to maximize our potential in the development of the novel exosome platform technology.

Clinical-stage Biopharmaceutical Company developing burfiralimab against Chronic hepatitis B and autoimmune diseases. Also Antibodies and small molecules are in the pipeline for oncological and immunological disorders.

ImmuneOncia is an immuno-oncology-centric biopharmaceutical company. Established in 2016 as a joint venture company between Yuhan and Sorrento, ImmuneOncia will leverage both companies’ expertise in drug development and antibody engineering. Our mission is to bring safe, effective, and novel immunotherapies to oncology patients world-wide. ImmuneOncia’s portfolio includes diverse immune checkpoint antibodies; the lead antibody IMC-001 Phase I study was completed in Feb 2019 and its Phase 2 study is being prepared. ImmuneOncia is also developing several antibodies targeting novel immune-checkpoints.

ImmunoForge is a biopharmaceutical company that specializes in developing targeted cancer agents for conditions like sarcopenia and rare mutations including BCR-ABL, T315I, RET, and FGFR4.

InnobationBio Co., Ltd., headquartered in the Republic of Korea, is a biotechnology company having established two major platforms. Its R&D capabilities are utilized to develop antibody and cell immunotherapy for cancer treatment, as well as liquid biopsy-based biomarkers.

Innon Energy LTD is a company that empowers Niagara engineers worldwide by supplying Building Automation companies with Niagara 4 products, training, and a 5-star service.

IntoCell is a Korea-based biotechnology company dedicated to the development and commercialisation of novel antibody drug conjugate (ADC) platform technologies.

Inventage Lab has the technology to mass-produce micro/nano drug delivery systems using microfluidics technology. Sustained-release injectables using polymeric microspheres have been commercialized, and lipid nano delivery systems such as liposome and LNP are now being manufactured.

ISU ABXIS is continuously striving to provide better treatment options for patients suffering from difficult-to-treat diseases based on Isu’s excellence in biotechnology.

JD Bioscience (JDB) possesses the core technology and experience to design small molecules for the treatment for a variety of diseases. With its ability and expertise, JBD is developing new drug candidates for metabolic-related diseases.

Jeil Pharmaceutical - Founded in 1959, Jeil has developed and supplied superior pharmaceutical products to promote the happiness and health of mankind and has contributed to the growth and development of the pharmaceutical industry in Korea. Jeil has been listed on KOSPI since 1988. As of 2018, Jeil is constituted of 1143 employees and has sales amount reaching above 680 billion Korean wons. The Central R&D Center established in 1980 forms the core of the R&D activities of Jeil. Currently, as of 2018, the new drug development laboratory, the pharmacology & toxicology laboratory, the organic synthesis laboratory, the formulation laboratory, and the analysis laboratory are actively engaged in conducting research into the complete manufacture and ingredients of innovative new drugs, incrementally modified drugs, and generic drugs. Jeil’s factory established in 1986 and located in Yongin-si, Korea was accredited as fulfilling KGMP in 1987, and produces tablets, capsules, injections, finished pharmaceutical products including patches, and Active Pharmaceutical Ingredients(APIs) such as anti-biotic ingredients, etc. The construction of new factory with the most up-to-dated facilities, which complies with EU-GMP and US-GMP, has been completed in 2016. In May of 2018, Jeil established Pharmaceutical Technology Research Institute, a formulation and analysis lab, at Yongin Technovalley in Yongin-si, Korea to further improve and invest in research and development of Incrementally Modified Drug (IMD) and generic products. Jeil, equipped with global-class research centers and production facilities, has been recognized for its outstanding value on the world market as well. In the ingredients sector, Jeil exports synthetic ingredients such as Cefditoren Pivoxil, Epinastine HCl, etc. to Japan and China, while also supplies finished products such as Kefentech Plaster (Ketoprofen), Cilapenem Injection (Imipenem / Cilastatin Sodium), etc. to more than 40 countries in ASEAN, Central and South America, Africa, etc. Within the South Korean market, Jeil operates a well-trained MR organization to cover the nation-wide market based on science and evidence, and thereby has become a supplier of over 70 prescription drugs and over 30 over-the-counter drugs. Beginning in the period between 1970 and 1980, Jeil has engaged in technological partnerships (licensing) with global pharmaceutical companies to provide the domestic market with outstanding new drugs. It has also been the first Korean company to engage in co-promotion successfully with the globally renowned company Pfizer, executing a win-win strategy with our overseas collaborative partners and thus winning recognition as an advanced pharmaceutical company adapted to internationalized business practices. We thank all of the visitors to our Jeil’s homepage for their interest and encourage you to contact us for further business progress.

JW Pharmaceutical Corp. (formerly Choongwae Pharma) is one of the leading pharmaceutical companies in Korea with core competencies in antibiotics, IV solutions, and anti-cancer treatments. JW is currently exploring targeted therapies in oncology leveraging the collaborative research and development strengths from the JW Drug Discovery Center in Korea and the JW Theriac Corp in the US. This R&D pipeline is driven by our platform technologies that have the potential to eradicate cancer stem cells selectively through a molecularly targeted approach. ------- JW Group consists of JW Holdings, JW Pharmaceutical, JW Medical, JW ShinYak, JW Industrial, JW Life Science, and JW Creagene. JW possesses i) magnificent sales force (900 reps) for the hospital market, ii) strong relationships with managements of hospitals & and hospital pharmacies, iii) excellent rapport with key opinion leaders in endocrinology, gastroenterology, oncology, cardiology, nephrology, urology and the general surgery therapeutic areas. JW's total sales revenue of US $ 0.7 billion was derived from Korea and other several Asian countries in 2012

치료 약물이 없는 뇌퇴행성 질환과 암 질환을 타겟으로 한 혁신 신약 개발 전문기업

Kanaph Therapeutics is developingtherapeutics for oncology by using bi-specific antibodies and small molecules that have a greatly enhanced immuno-stimulatory activity in the tumor micro-environment (TME).

KoBioLabs is recognized for its international level of microbiome therapeutic technologies. In particular, our researchers have a distinctive position in the microbiology field globally with their presence in the ongoing International Human Microbiome Consortium [IHMC].

Kolon Pharmaceutical, Inc. was established in 1958 with a mission to contribute on happiness of mankind and social welfare by enhancing people’s quality of life and providing top medical service thru development of innovative drugs with its respect for life and health. Kolon Pharmaceutical is a subsidiary of Kolon group which is one of the biggest industrial conglomerates of Korea that has core business domains in pharmaceuticals, biotechnology, cutting-edge materials, fashion, construction, environment, trade and IT. Kolon group’s health business unit is composed of three subsidiaries and they are Kolon Pharmaceuticals, Kolon Life Science(biotechnology) and Kolon Wellcare(drug store business). Kolon Pharmaceutical developed many outstanding products like Bicogreen for constipation, cold remedy Comy syrup & tablet, anti-fungal drug Konitra and Tamsulo capsule for prostatism with its own technology and also co-developed Brexin tablet(β-Cyclodextrin Prioxicam), Remicut SR capsule(Emedastine difumarate) and Pransus syrup(Pranoprofen) with outstanding pharmaceutical companies like Chiesi, Hisamitsu and Organon since its establishment. Kolon Pharmaceutical is also expanding its global presence by exporting its quality products like Flavon(Ginko biloba ext.), Diverine(Gliclazide), Tavisin(Ofloxacin), Clovana(Diclofenac) and Turant(Acetylcysteine) to Vietnam, Pakistan, Yemen and many other Middle Eastern countries. Our continuous efforts led us to fruitful outcomes in significant areas of our business especially new molecule research, joint research, development of API, new formulation and combination new drug.

LegoChem Biosciences, Inc. (LCB) is a research-based biotechnology company dedicated to the discovery, development, and commercialization of innovative medicines by leveraging our chemistry expertise to make conventional biologics more targeted and potent for the benefit of patients with diseases of highly unmet medical needs. We are advancing sustainable pipelines in therapeutic areas within antibiotics, anti-coagulants, oncology, antibody-drug conjugate (ADC), and protein-drug conjugate (PDC).

LG Chem is a leading global chemical company with a diversified business portfolio in the key areas of petrochemicals, advanced materials, and life sciences. The company manufactures a wide range of products from high-value added petrochemicals to renewable plastics, specializing in cutting-edge electronic and battery materials such as cathodes, as well as drugs and vaccines to deliver differentiated solutions for its customers. LG Chem is committed to reaching carbon-neutral growth by 2030 and net-zero emissions by 2050 by managing the impacts of climate change and making positive contributions to society through renewable energy and responsible supply chains.

LigaChem Biosciences (formerly LegoChem Biosciences, Inc.) is a clinical stage biopharmaceutical company focused on the development of novel therapeutics utilizing its proprietary drug delivery technologies and therapeutic antibodies. The company's pipeline includes antibody-drug conjugates (ADCs) and immuno-oncology therapeutics for the treatment of cancer and other serious diseases. LigaChem Biosciences is headquartered in Daejeon, South Korea, with additional offices in Seoul. The company has entered into co-development and license agreements for its ADC programs and has completed acquisitions by other companies. LigaChem Biosciences is committed to advancing innovative treatments for patients in need.

MDimune - The ultimate goal of MDimune Inc. is to provide an innovative platform technology that can revolutionize the paradigm of human therapeutics by achieving target-specific delivery of effective drugs. The precision of this novel technology will enable safer and more effective treatments of many debilitating human diseases and bring hope to patients.

MEDIPOST is founded in 2000, and today MEDIPOST is leading the global stem cell therapeutics field with the world’s first regulatory-approved allogeneic human Umbilical Cord Blood-derived Mesenchymal Stem Cell(hUCB-MSC) product named CARTISTEM® for patients with knee Osteoarthritis(OA), launched in Korean market in 2012. MEDIPOST operates the largest private cord blood bank “CELLTREE®” in Korea with over 255,000 units of private cord blood units under storage. Each year, over 20,000 private cord blood units are collected and stored at CELLTREE®. MEDIPOST’s research and development is focused on novel off-the-shelf, allogeneic cell therapeutics using human Umbilical Cord Blood-derived Mesenchymal Stromal Cells (hUCB-MSCs) with clinical-stage assets in the disease areas of osteoarthritis (OA), broncho-pulmonary dysplasia (BPD) and Alzheimer’s disease (AD). MEDIPOST’s flagship product, CARTISTEM® (allogeneic Umbilical Cord Blood-derived MSCs + hyaluronic acid hydrogel composite) for knee osteoarthritis was approved in 2012 by Korea’s regulatory agency Ministry of Food and Drug Safety (MFDS) with Biologics License Application (BLA) label “Treatment of knee articular cartilage defects in patients with osteoarthritis (ICRS grade IV) as a result of degenerative disease or repeated trauma (without age limit)” PNEUMOSTEM® (allogeneic Umbilical Cord Blood-derived MSCs) for the prevention of Bronchopulmonary Dysplasia (BPD) in premature infants, completed the first-in-human Phase I safety trial in Korea and the randomized, placebo-controlled Phase II clinical trial is ongoing in Korea. Phase I/II clinical trial in the U.S. has been completed confirming safety with positive efficacy signals. MEDIPOST’s 2nd generation human Umbilical Cord Blood-derived Mesenchymal Stromal Cell (hUCB-MSC) pipeline code named SMUP-IA-01 is an off-the-shelf intra-articular injectable cell product for the patients with early to mid-stage knee osteoarthritis (OA).

MEPSGEN, a biotech founded by YongTae Kim and Robert Langer in 2019, develops microengineered physiological systems so called organ-on-a-chip and uses the manufactured systems to study pathophysiological mechanisms of key diseases and screen new drug candidates for the treatment. With these studies supported by the technologies, the company has its own multiple new drug candidates, representative ones of which target Alzheimer's and brain tumors. The company specializes in developing and producing a 3D cell culture Microphysiological System platform and in discovering new therapeutics using nanomedicine technology. The products and services include improved accuracy in evaluating new drug candidates and reducing cost and duration of the development. The company carries out fundamental biological research and drug candidate test in an environment equipped with an organ-level function of connected human tissues, rather than studying in a traditional in-vitro experimental model using 2D cell culture, thereby enabling researchers to further verify the findings in more pathophysiologically relevant environments. MEPSGEN is holding many patents, patents pending, and numerous IP licenses in the biotechnology field. For more information visit www.mepsgen.com [ Industry ] Drug Discovery Drug Delivery Biotechnology [ Technology ] MEPS-X series - 3D Microphysiological System platforms MST-X series - Microvortex System, Nanoparticle manufacturing platform MG-X series – Nanomedicine, Biomimetic nanomaterial-based targeted drug delivery platforms

Over the past decades, focusing on a battery of conventional genes/proteins involved in the neurodegeneration has been disappointing in the field of neurodegenerative therapeutics. With the scientific responsibility and integrity, Neuracle Science is a clinical stage biotech company specialized in the development of breakthrough therapies for those who are living with serious and devastating neurodegenerative diseases. We provide a foundation for disease-modifying treatments for neurodegenerative diseases, discovering a completely novel and invaluable gene/protein target with unknown significance using non-biased study. Neuracle Science is based in Seoul, South Korea. We were founded in 2015 by scientific leaders in neuroscience, bioinformatics-based drug discovery, GPCR-mediated signaling, and antibody drug.

Novelty Nobility Inc. is a private clinical stage biotech company located in Pangyo, South Korea, and Boston, Massachusetts. We are currently focused on the research of novel angiogenesis targets and develop antibody-based therapeutics in ophthalmology and oncology, where angiogenesis plays a key pathogenic role. Novelty Nobility, a unique name for a biotech company, stands for what we pursue – Novel Science, Noble Management. The emblem in the middle of our logo, which shapes a drug, symbolizes our belief that a new drug is born when novel science meets noble management.

Novorex is specialized company in the development of new small molecule drugs targeting mostly oncology and neurology diseases using FBDD and artificial intelligence with pharmaceutical experts. Seamless Drug Discovery is performed using cutting-edge technology that considers the entire process of new drug development. We aim to develop high-efficiency new drugs through drug design that combines biophysical analysis and in vitro/in vivo assay.

인류는 현재 주목할 만한 시대를 살고 있습니다. 우리의 수명은 길어졌으며 앞으로 더욱 더 길어질 것입니다. 여기서 우리는 한가지 질문을 가져봐야 합니다. “진정 늘어난 수명이 행복한 삶이 될 것인가?” 행복한 삶은 오래 사는 것만이 아니라 아름답고 건강하게 살아가는 것입니다. 올리패스는 행복의 새로운 문을 열고자 합니다. 우리는 이러한 기대를 충족시키기 위해 2006년부터 기존 약물의 한계를 극복한 PNA(Peptide Nucleic Acid) 플랫폼을 개발하는데 최선을 다해 오고 있습니다. 올리패스는 차세대 RNA 치료제 개발을 선도하는 생명과학 기업입니다. 모든 질병과 노화를 극복하기 위해서는 각각의 세포들이 건강하고 젊게 유지되어야 합니다. 이 믿음을 갖고 우리는 RNA 치료제 기술을 통해 삶의 질을 획기적으로 높이는 꿈에 다가가고 있습니다. 올리패스에서는 다양한 분야의 과학자들이 각각의 세포들을 치유하고 완전하게 할 수 있는 방법을 찾기 위해 끊임없이 노력하고 있습니다. OliPass PNA 플랫폼 기술을 통해 우리가 이루고자 하는 꿈은 최고의 기술을 저렴하게 널리 쓰일 수 있게 개발해 전 세계 모든 사람들이 의료비 걱정없이 행복하고 건강한 삶을 살 수 있게 하는 것입니다. We are living in remarkable times, in fact when you think about it, over the past 100 years the life expectancy around the globe has almost doubled and we continue, of course, to constantly hope for even greater longevity. But we need to ask ourselves, does this increased longevity lead to a happier life? We all agree that true happiness does not result from just living longer, but also from living well. At OliPass, our mission is to open the door to a new era of healthy and beautiful aging. Since 2006, OliPass has been committed to revolutionizing the life sciences and improving the quality of life. Our research is focused on developing a new generation of therapeutics using our novel PNA based technologies. Thanks to our dedicated team and their hard work, OliPass is now a leading biotech company with OliPass PNA Platform Technology and a growing presence throughout the globe. At OliPass, scientists from diverse fields are constantly working together to find the cures for all diseases. With our innovative OliPass PNA platform technology, our goal is to make the highest quality of science affordable and accessible, so that everyone around the world can enjoy a happy, healthy life. OliPass is dedicated to providing safe and feasible options for healthy aging.

OliX Pharmaceuticals is a clinical stage pharmaceutical company developing therapeutics based on the science of RNAi to address a wide variety of illnesses. The Company has developed core platforms (asymmetric siRNA, cell-penetrating asiRNA) targeting locally administrable diseases, such as hypertrophic scars, hair loss, and age-related macular degeneration (AMD). OliX's third RNAi therapeutic platform, GalNAc-asiRNA, targets multiple liver diseases, including NASH/diabetes and HBV. For the general welfare of human beings, OliX is constantly endeavoring to become a leader in the global biotechnology industry by innovating and expanding its pipeline, even to the undruggable diseases.

We are an AI biotech specializing in drug development based on transcriptomic database. We strive to develop treatments for intractable and rare disease both in oncology and non-oncology space. We partner with pharmaceutical companies and i) identify the optimal indications of NCE under development, ii) identify the proper indications for clinical stage failed compounds, iii) screen combination drugs that can significantly increase the efficacy synergistically, iv) finding the optimal cancer biomarker, and v) identifying the primary site for carcinoma of unknown primary. While our AI technology offers platform to minimize cost, time, and risk of clinical failure for drug candidates, our desire to provide alternative cost competitive treatments for patients with rare and intractable disease are embedded in everyone at ONCOCROSS. Accelerate Drug Development with ONCOCROSS.

Founded in 1996, OSANG Healthcare is a leader in the In-Vitro Diagnostics (IVD) market and is one of the fastest-growing medical device manufacturing and distribution company in the nation, employing over 315 industry experts (52 in Research & Development/27 + PhD/MSc) We are at the forefront of manufacturing premium diagnostic devices, specializing in blood glucose, HbA1c, cholesterol, PCR testing solutions to over 110 countries worldwide. Our commitment to excellence was demonstrated during the pandemic when we became a pivotal supplier of COVID-19 test kits globally, showcasing our agility and dedication to public health. In 2023, we distributed 100 million COVID-19 Antigen Tests nationwide through Federal Agencies, and the only company in the world to be selected by National Institutes of Health(NIH) Independent Test Assessment Program(ITAP) twice for both OHC COVID-19 Antigen Test and COVID-19/Flu Antigen Test. Our goal is to be the premier researcher and developer of diagnostic sensors for a comprehensive range of diseases, ensuring a healthier future for all. Contact Us: sales@osangllc.com

“At Oscotec, our mission is to create values by translating cutting edge science into innovative medicines for clinically unmet needs”

Panolos Biosciences is at the forefront of structure-based protein design, ceaselessly pushing the limits of multi-specific drug development. We are dedicated to the creation of anti-angiogenic therapies for the treatment of cancer, autoimmune, and rare diseases. Our unique patented technology, "Alpha(α)-ART (Anti-angiogenesis-based Artifact Re-targeting Tri-specific)", employs a VEGF receptor backbone to develop mono or multi-specific antibody therapeutics, amplifying their potency.

Established in 1997, Peptron focuses on platform technology and clinical developments. Referred to as "Cozy-Cure," Peptron's highest priority is promoting and promising the best quality of life for patients with better treatment options, compliance, and price advantage. Peptron members' expertise in drug discovery and research, business development and strategic planning, drug delivery and formulation, GMP production, and Quality Control has helped develop peptide-based platform technology, SmartDepot™. SmartDepot™ brings the initial research process to the final medication development and successful commercialization phase with superior competitiveness. In line with proprietary technologies, we develop sustained-release (SR) medications to extend the release profile of the drug from weekly to monthly. Further, Peptron values global CDMO business. In the last few years, we have successfully formulated working with global companies with our in-depth expertise and resources. Peptron can work with you to achieve formulation development, regulatory approval and commercial manufacturing.

PharmAbcine is a clinical stage public company developing next generation IgG based therapeutics to treat cancer, neovascular eye diseases, and vascular related unmet needs. PharmAbcine has its own HuPhage library and innovative selection system. This technology provides therapeutic antibodies for a wide spectrum of indications in oncology, immuno-oncology, ophthalmology, pulmonology etc. PharmAbcine's advanced 3G expression system accommodates high levels of antibody production and steady reproducibility. With these cutting-edge technology platforms, it provides state of the art antibody generation services. PharmAbcine has focused on the development of novel antibody therapeutics since the company’s foundation in 2008 and laid the groundwork for the commercialization of Olinvacimab, PMC-309, PMC-403, and PMC-402. We will also become an innovative global biotech company through the development of other new candidates such as PMC-005BL, PMC-122, PMC-401, and PMC-401s.

PharmCADD is a company designed to accelerate drug discovery meanwhile performing a design without building or maintaining the infrastructure associated with high-performance computational resources. The platform for both the design and discovery in the PharmCADD is composed of the state-of-the art technology: AI (Artificial intelligence), Molecular Dynamics (MD), Quantum Calculation (QC), and Network theory. AI, which is data-derived technology emerges as a new trend which could potentially be very revolutionary in our modern world. It enables customers to accelerate the search for a certain or specific drug candidate in the vast existence of chemical space. On the other hand, MD and quantum calculation, physics-based technology, enables the customers to characterize potential drug candidates more precisely. The effective combination of the data-derived and physics-based technologies leads to more accurate and speedier drug discovery.

We are a biotech company developing new treatments for patients resistant to existing therapies based on innovative new drug modalities such as antibody-drug conjugate(ADC). Based on our strong R&D capabilities, we have built our next-generation ADC platform PINOT-ADC™ independently and have been working with various partners to research new ADC anticancer treatments. In addition, clinical development and commercialization of NTX-301, a targeted anticancer drug for blood/solid cancer, and NTX-101, a treatment for glaucoma, are underway.

Pin Therapeutics - "Creating Therapeutic Products Degrading Disease-causing Proteins"​

Prazer Therapeutics is a biotechnology company pioneering innovative therapeutics for various intractable diseases using rational drug design and next-generation targeted protein degradation (TPD) platform called SPiDEM. Our SPiDEM-based drug candidates for neurodegenerative diseases, cancers and inflammatory diseases have demonstrated superior pharmacokinetics and efficacy as well as reduced drug resistance compared to currently available TPD technologies. Our pipeline also encompasses anti-viral therapeutics to treat chronic hepatitis B (CHB) caused by hepatitis B virus (HBV) as well as acute lung inflammation caused by coronaviruses, influenza viruses and respiratory syncytial virus (RSV).

Quratis Inc operates as a developer of vaccines and therapies designed to treat tuberculosis. The company develops youth and adults tuberculosis vaccines, messenger ribonucleic acids, and other related immune-related vaccines.

Founded in 2008, Qurient takes a pioneering position in the newly emerging biotech industry in Korea. Qurient introduced a unique virtual biotech model, running R&D operations not only in clinical development phases, but also in early discovery research stage, named ‘Network R&D’ model. Network R&D aims to capital efficient innovation, being able to tackle on new scientific innovations in various therapeutic areas through experts network. Qurient mainly engages in value creation between early discovery to clinical proof-of-concept. The particular concentration in the value chain creates more efficient organizational structure with clear focus on innovation. Qurient believes late stage development is better handled by fully integrated pharmaceutical/biotech industry with proper marketing function in the therapeutic area. Qurient’s mission is to provide innovation for unmet medical needs to help patients around the world. Through fulfilling the mission, Qurient will be able to create concrete value for its shareholders.

ReCerise Therapeutics is a biotechnology company that focuses on developing first-in-class therapeutics and diagnostics targeting liver-specific proteins.

[About ROKIT Healthcare] ROKIT Healthcare is a First Mover in regenerative healthcare, pioneering innovations that reduce medical costs for governments and patients while driving healthcare transformation. Our mission is to extend healthy lifespans and enhance quality of life through cutting-edge technologies. At the heart of our vision lies the AI Hyper-Personalized Organ Regeneration Platform, a revolutionary solution designed to meet critical medical needs and redefine the future of medicine. [What We Do] - AI-Driven Organ Regeneration: Combining advanced bioprinting and AI to deliver hyper-personalized therapies for organ and tissue regeneration. - Anti-aging Bio-suppliment Products: Leading the anti-aging market with NMN, offering scientifically proven and effective solutions for better health. (ROKIT America) - Genomics: Utilizing AI-powered single-cell RNA-seq analysis to develop innovative diagnostics and precision medicine. (ROKIT Genomics) [Why ROKIT Healthcare?] We are committed to creating a sustainable and innovative healthcare ecosystem that benefits governments, healthcare providers, and patients. By addressing the root causes of medical challenges and reducing costs, we aim to make advanced healthcare accessible to all. [ROKIT Healthcare에 대하여] - ROKIT Healthcare는 재생 의료 분야의 First Mover로서, 정부와 환자의 의료비를 절감하고 의료 혁신을 주도하는 기술과 아이디어를 선도하고 있습니다. -우리의 사명은 최첨단 기술을 통해 건강 수명을 연장하고 삶의 질을 향상시키는 것입니다. 이러한 비전의 핵심에는 AI Hyper-Personalized Organ Regeneration Platform이 자리 잡고 있으며, 이는 의료의 중요한 과제를 해결하고 미래 의료의 패러다임을 재정의하는 혁신적인 솔루션입니다. [우리가 하는 일] - AI 기반 장기 재생: 첨단 바이오프린팅과 AI를 결합하여 개개인 맞춤형 장기 및 조직 재생 치료를 제공합니다. - 항노화 바이오 보충제 제품: 과학적으로 검증된 NMN으로 항노화 시장을 선도하며 건강을 위한 효과적인 솔루션을 제공합니다. (ROKIT America) - 유전체학: AI 기반 단일 세포 RNA-seq 분석을 활용하여 혁신적인 진단 및 정밀 의학 솔루션을 개발합니다. (ROKIT Genomics) [ROKIT Healthcare가 특별한 이유] 우리는 정부, 의료 제공자, 그리고 환자 모두에게 혜택을 주는 지속 가능하고 혁신적인 의료 생태계를 만들기 위해 노력하고 있습니다. 의료 문제의 근본적인 원인을 해결하고 비용을 절감함으로써, 선진 의료 기술을 모두가 접근 가능하게 만드는 것을 목표로 하고 있습니다.

Rznomics is developing safe and effective biopharmaceuticals in oncology, degenerative disease, and genetic disease based on RNA platform technology called trans-splicing ribozyme. Acknowledged by bio-focused institutions, Rznomics has raised \23.7 billion from series A& B and recently raised \37.2 billion from series C, resulting in a total of \60.9 billion of fundraising. Also, Rznomics received \8 billion for the new drug development research funding from the government. In 2022 1H, Rznomics’ RZ-001 IND submission for the HCC treatment was approved by MFDS, and the clinical trial for the RZ-001 is currently running. In addition to the RZ-001, Rznomics has competitive and innovative pipelines, such as glioblastoma multiforme, Alzheimer’s disease, genetic ocular disease (retinitis pigmentosa), and circular RNA technology. Rznomics is also actively partnering with global companies to discuss collaboration opportunities in co-research, co-development, and licensing.

Established in 2012, Samsung Bioepis is a biopharmaceutical company committed to realizing healthcare that is accessible to everyone. Through innovations in product development and a firm commitment to quality, Samsung Bioepis aims to become the world's leading biopharmaceutical company. Samsung Bioepis continues to advance a broad pipeline of biosimilar candidates that cover a spectrum of therapeutic areas, including immunology, oncology, ophthalmology, endocrinology, hematology and nephrology. For more information, please visit: www.samsungbioepis.com. To see our community guidelines, please visit: bit.ly/2l0yiI3

Selecxine is a biopharmaceutical development company specialized in the field of immunotherapeutics. Selecxine strives to develop immunotherapeutics – a new paradigm of pharmaceuticals– through a specialized antibody development process, using an innovative platform technology of functional antibody screening and development. We endeavor to improve the survival rate and quality of life of cancer patients by developing anti-cancer immunotherapeutics that selectively stimulate the immune cells. These agents act against tumor cells through the regulation of cytokine function, which plays a key role in the enter cell activities. Based on our technology and expertise in the pharmacology and development field, we aim to provide safe and efficient therapeutics and innovative solutions for next-generation pharmaceuticals.

Shaperon is a clinical stage biotech company developing novel inflammasome inhibitors(small molecule). Its unique mechanism of action of GPCR-regulated P2X7 inhibition suppresses a broad spectrum of inflammatory cytokines including IL-1β, IL-18, IL-6, and TNF-α, etc. by controlling both priming and activation phase of inflammasome, whereas conventional approaches are designed to suppress only the activation phase. With this unique and novel modality which is best suited to address complex immune-mediated inflammatory disorders, we are currently developing multiple clinical programs in atopic dermatitis, cytokine release syndrome, Alzheimer’s disease, ulcerative colitis, NASH, etc. In addition to inflammasome R&D programs, Shaperon has anti-viral, anti-cancer nanobody therapeutics. Shaperon’s proprietary immunized nanobody libraries combined with high throughput screening and in vitro/in vivo system enable us to fast forward the realization of advantages of Nanobodies over conventional antibody-based medicines. We currently developing multi-valent, multi-specific Nanobodies in multiple delivery forms in oncology and viral infection diseases.

SHINPOONG PHARMACEUTICAL CO.,LTD. is a pharmaceuticals company based out of 733-23 Yoksam-Dong,Kangnam-Gu,Seoul, Seoul, South Korea.

SillaJen Biotherapeutics, Inc. is located in San Francisco, one of the largest and most innovative biotech clusters in the world. Sillajen Biotherapeutics focuses on the research, development and manufacturing of oncolytic viruses to treat cancer; we are responsible for Clinical Operations, Regulatory Affairs, Research and Development, Manufacturing, Alliance Management and Accounting for clinical trials. SillaJen, Inc. is a South Korean based biotechnology company headquartered in Busan South Korea, with satellite offices in Seoul, South Korea and San Francisco, CA. The company is focused on the development and commercialization of oncolytic immunotherapy products using the SOLVETM platform, including its lead product Pexa-Vec, which is currently in Phase 3 trials for the treatment of advanced primary liver cancer. Additional information about SillaJen is available at www.sillajen.com.

SK Biopharmaceuticals is a part of the global conglomerate SK Group, the second largest company in Korea. We’re responsible for the development of innovative next-generation drugs within SK Group. SK Biopharmaceuticals has been developing many new drug candidates in the area of CNS, led by the clinical development center(SK Life Science) located in United States and the research center in Pangyo Techno-valley, Gyeonggi-do. With the experience and expertise in the CNS area, SK Biopharmaceuticals will continue to thrive as a successful new drug development company and become a trusted partner through its global R&D network. By 2020, SK Biopharmaceuticals envisions to grow into a global Fully Integrated Pharmaceutical Company (FIPCO) with streamlined capabilities from research to marketing. For more information, visit our website at www.skbp.com.

At SK bioscience, we work everyday to promote human health from prevetion to cure. We have successfully developed South Korea's first COVID-19 vaccine, 'SKYCovione' through global cooperation with the Bill & Melinda Gates Foundation, CEPI, GSK, etc., and a universal vaccine to prevent ‘Sarbecovirus.’ We have also developed the world's first quadrivalent cell-cultured influenza vaccine, SKYCellflu with obtaining WHO PQ (Pre-qualification) certification in 2019 followed by developing SKYZoster, the world's second shingles vaccine, and SkyVaricella, the world's second WHO PQ-certified chickenpox vaccine. We are expanding our R&D pipeline through global partnerships with public and private institutions, and is planning to commercialize a pneumococcal conjugate vaccine, cervical cancer vaccine, typhoid conjugate vaccine, and rotavirus vaccine. In addition, SK bioscience signed a CMO contract to manufacture AstraZeneca's COVID-19 vaccine from drug substance to drug product at L-House, SK bioscience’s vaccine manufacturing plant, and contributed to the early prevention of COVID-19, recognized as a global hub for vaccine manufacturing. Based on innovative technology, all pf our colleagues are trying to achieve the company’s mission, ‘We promote human health, from prevention to cure.’ To meet social expectations, SK bioscience will build trust as a global innovative partner of vaccine and biotech so that all stakeholders, including employees, customers, shareholders, and local communities, could be proud and happy.

SN BioScience specializes in cutting-edge drug delivery systems, developing innovative technologies, and bringing competitive new drugs to market, with a strong focus on oncology products.

SPARK Biopharma - We Provide Small-molecule Therapeutics using Phenotypic Discovery for Improving Human Health.

Surginex is a company that operates a drug discovery platform intended to develop next-generation bio platforms and new drugs. The company specializes in 361 HCT/P allografts and is committed to turning innovative scientific research into practical medical solutions.

Therabest is a biopharmaceutical company that develops iPSC-derived immune cells. Our mission is to provide the benefits of cell therapy to many patients. We established a robust process that manufacture Armored iPSC CAR-NK, off-the-shelf cell products using our exclusive technology. Currently, our main pipeline is CD19 (Lymphoid tumor) and Muc1c (Solid tumor). We plan to expand our pipeline through collaboration with companies that own tumor target scFv.

TiumBio (KOSDAQ: 321550) is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapeutics for patients with rare and incurable diseases. Our mission is to enhance the hope and happiness of humanity through scientific advancements. TiumBio currently has three leading pipeline assets in clinical trials, with TU2218 being investigated in Phase 2 and TU2670 and TU7710 in Phase 1. TU2218 is an oral immuno-oncology therapy targeting TGF-beta and VEGFR2, while TU2670 is an orally active non-peptide GnRH antagonist. Additionally, TU7710 is a bypass-factor treatment specifically designed for hemophilia patients who have developed neutralizing antibodies. TiumBio is located in Seongnam-si, South Korea and has three subsidiaries including Boston-based biotechnology company, Initium Therapeutics and a CDO compnay, Protium Science.

Toolgen is committed to conducting research for revamping genome editing technology and thus developing not only therapeutics for humans but plants and animals of which the genetic characters are modified by the editing.

Vaxdigm is a biotechnology company focused on the development of improved vaccines and future vaccines.

ViGenCell is a medical company that specializes in immune cell therapy.

Wellmarker Bio is a spin-off company from Seoul Asan Medical Center(AMC), which is the largest and most renowned hospital in the Republic of Korea. We specialized in developing predictive biomarkers and first-in-class drugs through profound research know-hows and Research Institute that is comprised of Target discovery department, Drug discovery department, Medicinal chemistry department and CMC department.

At Xcell Therapeutics, we believe that scientists and researchers should have the opportunity to develop groundbreaking treatments to cure disease, ensure good health, and limit animal suffering in research. That's why we have develop and produce serum-free, chemically defined media that provides for better research results and greater consistency in manufacturing. Our media is carefully designed and manufactured with precision to help our customers in bioengineering and life sciences achieve a better future for humanity.

Y-Biologics is Korea’s leading R&D biotech company in the field of antibody drug development. Since establishing Y-Biologics in 2007, our company has focused on the research and development of antibody therapeutics, successfully building two main platform technologies: Ymax®-ABL, a unique human antibody library, and ALiCE, a novel format for bispecific T-cell engager antibodies. Utilizing our excellent and differentiated platform technologies, we are striving to become a leading global antibody drug development company in the field of immuno-oncology. Here at Y-Biologics, with our full-cycle antibody development capabilities, we are pursuing full-fledged development of immuno-oncologic drugs using our bispecific antibody platform. We aim to address unmet medical needs by developing a next-generation immunotherapeutics with higher patient response rates and superior efficacy in comparison to existing immuno-oncology drugs. Y-SERVICE Technologys_Antibody Screening, Protein Expression, Cell Line Development, Analysis Service

YDGLS develops new drugs for various diseases and development & sales of precision medical products & apparatus and healthcare products.

Yuhan Corporation is an integrated healthcare company founded in 1926. It has achieved top market value and sales revenue in Korean pharmaceutical industries, and been awarded for the most respected and trusted company in Korea for recent 11 consecutive years. It has two subsidiaries, Yuhan Chemical and Yuhan Medica, and the affiliates including Joint Ventures with Janssen(Belgium), the Clorox Company(USA), and Kimbery-Clark Corporation(USA). The core business of Yuhan can be classified into Primary & Specialty care, Dietary supplement, Household & Animal care, and contract manufacturing of active pharmaceutical ingredients.

Zymedi is a clinical-stage biopharmaceutical company focused on transforming the role of ARSs (Aminoacyl-tRNA Synthetases) as a novel target for discovering and developing treatments for serious, life-threatening conditions lacking effective therapies or standard care. Our lead asset, ZMA001, is a first-in-class therapeutic that targets Lysyl-tRNA synthetase 1 (KARS1). By controlling monocyte and macrophage infiltration to inhibit inflammation in pulmonary blood vessels, ZMA001 is being developed as a treatment for pulmonary arterial hypertension (PAH). Currently in Phase I trials through a CRADA with the U.S. NIH, ZMA001 shows promise in addressing the root causes of PAH, a market projected to reach $9.7 billion by 2028.